- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05168462
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction (NORSHOCK)
Rationale: Pump failure due to acute myocardial infarction (AMI) can lead to cardiogenic shock (CS): a state of low blood flow to end-organs with subsequent multi-organ failure that is associated with high mortality rated. The first line pharmacologic treatment strategy in CS is noradrenaline. This vasopressor drug is used to maintain adequate blood pressures. The assumption is that a mean arterial blood pressure (MAP) ≥ 65 mmHg will improve flow and thereby tissue perfusion of myocardium and other tissues (e.g. renal). However, there is no evidence that an increase in MAP, if achieved by noradrenaline, leads to greater end-organ blood flow and better outcomes.
Objective: With this study the investigators aim to investigate the (cost-)effectiveness of reduced noradrenaline in patients with CS by using a lower MAP target of ≥ 55 mmHg, compared to ≥ 65 mmHg. The investigators hypothesize that reduced use of noradrenaline will improve overall survival and decrease renal failure requiring renal replacement therapy.
Study design: Open label, randomized controlled multicenter trial
Study population: Adults patients with CS due to AMI
Intervention: Treatment strategy of reduced noradrenaline, by using a lower MAP target ( ≥ 55 mmHg).
Main study endpoint: composite of all-cause mortality and severe renal failure leading to renal replacement therapy within 30-days after randomization.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Elma Peters
- Phone Number: 0205668380
- Email: e.j.peters@amsterdamumc.nl
Study Locations
-
-
-
Amsterdam, Netherlands, 1105AZ
- Recruiting
- Amsterdam UMC, location AMC
-
Contact:
- Jose Henriques
- Email: j.p.henriques@amsterdamumc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Acute myocardial infarction, STEMI or NSTEMI
- Early revascularization by PCI
- Cardiogenic shock, characterized by:
I. a. Systolic blood pressure (SBP) ≤ 90 mmHg for > 30 minutes, OR b. Use of drugs to maintain SBP > 90 mmHg at randomization.
II. Clinical signs of impaired organ perfusion with at least one of the following criteria:
- Altered mental status
- Cold, clammy skin and extremities
- Oliguria with urine output < 30ml/hour
- Serum lactate > 2.0 mmol/L
III. Clinical signs of pulmonary congestion
Exclusion Criteria:
- Resuscitation > 30 minutes
- Mechanical cause of cardiogenic shock (e.g. papillary muscle rupture, ventricular septal rupture)
- Onset of shock > 12 hours
- Imminent need for mechanical circulatory support
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Reduced noradrenaline (MAP ≥ 55 mmHg)
|
Reduced noradrenaline by using a lower MAP target
|
No Intervention: Usual care (MAP ≥ 65 mmHg)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality and renal failure
Time Frame: 30-days
|
Composite of all-cause mortality and severe renal failure leading to renal replacement therapy
|
30-days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood pressure (systolic and diastolic)
Time Frame: The first 24 hours
|
Blood pressure measured hourly during the first 24 hours of ICU/CCU admission
|
The first 24 hours
|
Heart rate
Time Frame: The first 24 hours
|
Heart rate, measured hourly during the first 24 hours of ICU/CCU admission
|
The first 24 hours
|
Enzymatic infarct size, measured by hs-Troponin T
Time Frame: 0, 6, 12, 24, 36 and 72 hours
|
Size of myocardial infarction, measured by hs-Troponin T
|
0, 6, 12, 24, 36 and 72 hours
|
Enzymatic infarct size, measured by CK-MB
Time Frame: 0, 6, 12, 24, 36 and 72 hours
|
Size of myocardial infarction, measured by CK-MB
|
0, 6, 12, 24, 36 and 72 hours
|
Need for mechanical circulatory support
Time Frame: Recorded after ICU/CCU discharge, assessed up to 60 days
|
Type of mechanical circulatory support device
|
Recorded after ICU/CCU discharge, assessed up to 60 days
|
Duration of mechanical ventilation
Time Frame: Recorded after ICU/CCU discharge, assessed up to 60 days
|
Duration of mechanical ventilation, expressed in days
|
Recorded after ICU/CCU discharge, assessed up to 60 days
|
Need for vasopressors / inotropes
Time Frame: Recorded after ICU/CCU discharge, assessed up to 60 days
|
The type of vasopressors / inotropes that were administrered
|
Recorded after ICU/CCU discharge, assessed up to 60 days
|
Ejection fraction, percent
Time Frame: 72 hours and 1 year
|
As measured by echocardiography and/or MRI
|
72 hours and 1 year
|
Renal function
Time Frame: 1 year
|
Renal function, measured by serum creatinin
|
1 year
|
Cost-effectiveness
Time Frame: 1-year
|
Cost per patients alive without severe renal failure and costs per QALY (quality-adjusted life year)
|
1-year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- Shock
- Hypotension
- Shock, Cardiogenic
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Norepinephrine
Other Study ID Numbers
- NL79416.018.21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
Isfahan University of Medical SciencesTehran University of Medical SciencesRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionIran, Islamic Republic of
Clinical Trials on Reduced noradrenaline use
-
University of Southern DenmarkEuropean Research CouncilCompleted
-
Drexel UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Rambam Health Care CampusRecruitingPreterm Labor | Respiratory MorbidityIsrael
-
Pennington Biomedical Research CenterAlliance for Potato Research and EducationCompleted
-
Bastyr UniversityMichael J. Fox Foundation for Parkinson's ResearchCompletedParkinson's DiseaseUnited States
-
Case Western Reserve UniversityNational Institute of Dental and Craniofacial Research (NIDCR); University... and other collaboratorsCompleted
-
University of AberdeenUnknownNon Coeliac Gluten SensitivityUnited Kingdom
-
Nathalie JohnsonCompleted
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruitingHead and Neck Squamous Cell CarcinomaChina
-
Lund UniversityActive, not recruitingAutoimmune Diseases | Celiac Disease in Children | type1diabetesSweden